CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the appointment of Sir Keith Peters FRS as Chairman of the Company’s Scientific Advisory Board (SAB).
“Sir Keith is a world-renowned expert in the field of clinical immunology and has made significant contributions to the development of new medicines by applying a better understanding of physiology to the development of novel therapies,” said Kevin Lee, Ph.D., Chief Executive Officer of Bicycle Therapeutics. “In addition, Sir Keith has been a torch bearer for clinical research through the assembly of cutting-edge academic research departments at a number of leading medical institutions. We thank our outgoing Chairman, Jose Carlos, for his excellent leadership of the Scientific Advisory Board over the last several years and are honored to now have Sir Keith serve as the Board’s new Chair.”
Jose Carlos Gutiérrez-Ramos said: “It has been a pleasure collaborating with the Bicycle team and supporting the advances the Company has made over the last few years as Chairman of the Scientific Advisory Board. I’m happy to welcome my fellow Bicycle SAB member Sir Keith into this role. As Bicycle’s clinical portfolio continues to expand, Sir Keith’s in-depth experience of clinical drug development will be a great asset for the Company.”
“I’ve served on Bicycle’s Scientific Advisory Board since its inception and in that time, have been impressed by the tremendous progress the company has made in applying its innovative technology to develop novel therapeutic candidates,” said Sir Keith Peters, Chairman of the Scientific Advisory Board. “I look forward to continuing to work with senior leadership to advance the Company’s growing pipeline of clinical assets in this new expanded capacity.”
Sir Keith Peters is Emeritus Regius Professor of Physic at the University of Cambridge, where he was also head of the School of Clinical Medicine. He is a fellow of the Royal Society, and fellow and past president of the Academy of Medical Sciences. Sir Keith’s industry experience includes membership of The Board of Advisers to Merck Research Laboratories and Senior Consultant in R&D to GlaxoSmithKline. In the biotech sector, he was a longstanding member of the scientific advisory board of Cambridge Antibody Technology. Prior to working in industry, Sir Keith held a number of academic appointments, including posts at the University of Birmingham, the National Institute for Medical Research at Mill Hill and the Welsh National School of Medicine. Sir Keith’s personal research has focused on autoimmunity, especially diseases of kidney and blood vessels, with emphasis on innovative treatments for these conditions. He earned his medical degree from the Welsh National School of Medicine.
About Bicycle Therapeutics
Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles®, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycles attractive candidates for drug development. Bicycle’s lead product candidate, BT1718, a Bicycle Toxin Conjugate (BTC) that targets MT1-MMP, is being investigated in an ongoing Phase I/IIa clinical trial in collaboration with the Centre for Drug Development of Cancer Research UK. Bicycle is also evaluating BT5528, a second-generation BTC targeting EphA2, in a Company-sponsored Phase I/II study. Bicycle is headquartered in Cambridge, UK with many key functions and members of its leadership team located in Lexington, MA. For more information, visit bicycletherapeutics.com.